

Supplementary material

Table A. Non-significant differences between aSLE and jSLE.

Variable	aSLE (n=3.428)	jSLE (n=484)	p-value
<i>Constitutional</i>			
Loss of weight	319 (9.4%)	52 (10.8%)	0.324
Mucocutaneous			
Photosensitivity*	1902 (57%)	287 (61.4%)	0.205
Discoid rash*	653 (19.5%)	100 (21.4%)	0.500
Cutaneous ulcers**	91 (2.6%)	15 (3.1%)	0.578
Scarring alopecia**	68 (2%)	9 (1.8%)	0.858
<i>Articular</i>			
Arthritis*	2515 (74.8%)	375 (78.2%)	0.206
Erosive arthritis**	339 (10.0%)	40 (8.4%)	0.279
Atrophy, muscle weakness**	81 (2.3%)	15 (3.1%)	0.324
Tendon rupture**	71 (2.1%)	5 (1.0%)	0.125
Avascular osteonecrosis	1.8±1.2 2 [1-2]	1.6±0.6 2 [1-2]	
<i>Respiratory</i>			
Interstitial alveolitis	128 (3.8%)	20 (4.2%)	0.648
Pulmonary embolism	100 (2.9%)	11 (2.2%)	0.432
Lung fibrosis**	69 (2.0%)	6 (1.2%)	0.247
Pulmonary hypertension**	81 (2.3%)	8 (1.6%)	0.343
Alveolar haemorrhage	30 (0.9%)	6 (1.2%)	0.417
Shrinking lung	29 (0.8%)	4 (0.8%)	0.967
Pulmonary infarction**	8 (0.2%)	1.0 (0.2%)	0.912
<i>Heart</i>			
Vascular disease**	198 (5.8%)	25 (5.2%)	0.597
Valve dysfunction**	103 (3.2%)	19 (4.0%)	0.313
Angina or by pass**	70 (2%)	6 (1.2%)	0.235
Myocarditis**	24 (0.7%)	3 (0.6%)	0.844
Number of heart attacks**	1.1±0.3 1.0 [1-1]	1.1±0.0 1.0 [1-1]	
<i>Vascular</i>			
Major tissue loss**	31 (0.9%)	3 (0.6%)	0.536
Venous thrombosis**	132 (3.9%)	3 (0.6%)	0.740
Intermittent claudication >6 months**	29 (0.8%)	1 (0.2%)	0.135
<i>Kidney</i>			
Creatinine units			
- µmol/L	32 (4.3%)	6 (3.5%)	
- Mg/dL	699 (95.6%)	164 (96.4%)	0.620
<i>Neuropsychiatric</i>			
Depression	565 (16.8%)	71 (15.0%)	0.344
Neuropathy**	111 (3.3%)	13 (2.8%)	0.602
Transverse myelitis**	28 (0.8%)	3 (0.6%)	0.657
N° strokes**	1.1±0.4 1 [1-1]	1.2±0.6 1 [1-1]	0.478
<i>Ophthalmological</i>			
Cataract**	296 (8.8%)	31 (6.5%)	0.095
Visual disorder*	112 (3.6%)	24 (5.1%)	0.312
Retinopathy**	140 (4.1%)	22 (4.6%)	0.636
<i>Gastrointestinal</i>			
Hepatitis	85 (2.5%)	13 (2.7%)	0.759
Pancreatic insufficiency	6 (0.1%)	1 (0.2%)	0.875
<i>Haematological</i>			
Leukopenia*	1907 (56.9%)	322 (68.1%)	0.594
Lymphopenia	248 (51.5%)	1964 (52.7%)	0.594
Haemophagocytic syndrome	14 (0.4%)	2 (0.4%)	0.984
Red aplasia	14 (0.4%)	1 (0.2%)	0.506
<i>Serological (immuno-haematological)</i>			
ANAS*	3383 (98.7%)	475 (98.5%)	0.676
Anti-RNP	788 (23.7%)	120 (26.0%)	0.276
Anti-La	634 (19%)	87 (18.8%)	0.894

Variable	aSLE (n=3.428)	jSLE (n=484)	p-value
<i>Other</i>			
MCTD	93 (3.2%)	7 (1.7%)	0.096
<i>Indexes</i>			
SLICC/ACR SDI	1.1 ± 1.6 1 [0-2]	1.2 ± 1.6 1 [0-2]	0.164
<i>Comorbidity</i>			
Alcoholism	142 (4.5%)	14 (3.1%)	0.427
COPD	101 (3 %)	7 (1.5%)	0.057
<i>Malignance**</i>			
Solid without metastasis	149 (4.4%)	15 (3.1%)	
Solid with metastasis	28 (0.8%)	0 (0%)	
Leukaemia	6 (0.1%)	1 (0.2%)	
Lymphoma	19 (0.5%)	2 (0.4%)	0.192
<i>Pharmacological treatment</i>			
Dose corticosteroids			
<10 mg	1370 (79.7%)	211 (75.3%)	
10-30 mg	275 (16.0%)	50 (17.8%)	
30-60 mg	50 (2.9%)	14 (5%)	
>60 mg	22 (1.2%)	5 (1.7%)	0.185
Antimalarials	2662 (81.8%)	382 (82.2%)	0.256
OAC	450 (14%)	63 (13.7%)	0.797
Methotrexate	540 (16.6%)	63 (13.1%)	0.099
Leflunomide	118 (3.5%)	14 (2.9%)	0.658
Anti-TNF	62 (1.9%)	9 (1.9%)	0.779
Abatacept	9 (0.2%)	1 (0.2%)	0.868
<i>Non pharmacological treatment</i>			
Plasmapheresis	45 (1.3%)	11 (2.3%)	0.077
<i>Comorbidities treatment</i>			
Angiotensin enzyme converter inhibitor	927 (29.7%)	137 (31.1%)	0.261
Diuretic	657 (20.9%)	90 (20.7%)	0.590

Table B. Mortality adjustment by SLE disease duration.

SLE disease evolution time (months)					
Exitus	Odds ratio	Std. Err.	z	p>[z]	[95% Conf. Interval]
SLEj	.4353939	.1318634	-2.75	0.006	.2404847 .788274
Follow-up time	.9990871	.0008423	-1.08	0.279	.9974377 1.000739
SLE disease duration time since first symptom (years)					
Exitus	Odds ratio	Std. Err.	z	p>[z]	[95% Conf. Interval]
SLEj	.4348503	.1279477	-2.83	0.005	.2442797 .774091
Disease evolution time	1.000546	.0079465	0.07	0.945	.9850917 .016243